136 related articles for article (PubMed ID: 21489835)
1. Management of residual non-retroperitoneal disease following chemotherapy for germ cell tumor.
Sadeghi N; Badalato GM; Kates M; McKiernan JM
Urol Oncol; 2011; 29(6):837-41. PubMed ID: 21489835
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
3. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
4. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
[TBL] [Abstract][Full Text] [Related]
5. Management of non-retroperitoneal residual germ cell tumor masses.
Katz MH; McKiernan JM
Urol Clin North Am; 2007 May; 34(2):235-43; abstract x. PubMed ID: 17484928
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Masterson TA; Shayegan B; Carver BS; Bajorin DF; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J
Urology; 2012 Jan; 79(1):156-9. PubMed ID: 22202548
[TBL] [Abstract][Full Text] [Related]
7. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
Yoon GH; Stein JP; Skinner DG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
[TBL] [Abstract][Full Text] [Related]
9. Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?
Medina-Polo J; Martínez-Silva V; Domínguez-Esteban M; de la Rosa-Kehrmann F; Villacampa-Aubá F; Castellano-Gauna D; Díaz-González R
Arch Esp Urol; 2011 Sep; 64(7):611-9. PubMed ID: 21965259
[TBL] [Abstract][Full Text] [Related]
10. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
[TBL] [Abstract][Full Text] [Related]
11. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis.
Sogani PC
Urol Clin North Am; 1991 Aug; 18(3):561-73. PubMed ID: 1652171
[TBL] [Abstract][Full Text] [Related]
13. Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
Stephenson AJ; Aprikian AG; Gilligan TD; Oldenburg J; Powles T; Toner GC; Waters WB
Urology; 2011 Oct; 78(4 Suppl):S444-55. PubMed ID: 21986224
[TBL] [Abstract][Full Text] [Related]
14. The management of stage I nonseminomatous testicular germ cell tumors.
Pectasides D; Farmakis D; Pectasides M
Oncology; 2006; 71(3-4):151-8. PubMed ID: 17646698
[TBL] [Abstract][Full Text] [Related]
15. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
[TBL] [Abstract][Full Text] [Related]
16. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection.
Ehrlich Y; Yossepowitch O; Kedar D; Baniel J
BJU Int; 2006 Jun; 97(6):1221-4. PubMed ID: 16686715
[TBL] [Abstract][Full Text] [Related]
17. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
[TBL] [Abstract][Full Text] [Related]
18. Late relapse (>2 years) on surveillance in stage I non-seminomatous germ cell tumours; predominant seminoma only histology.
Nolan L; Wheater M; Kirby J; Simmonds P; Mead G
BJU Int; 2010 Dec; 106(11):1648-51. PubMed ID: 20735393
[TBL] [Abstract][Full Text] [Related]
19. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
20. Management of advanced germ-cell tumors of the testis.
Fléchon A; Rivoire M; Droz JP
Nat Clin Pract Urol; 2008 May; 5(5):262-76. PubMed ID: 18398406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
